National Harbor (US): Top Indian pharmaceutical companies, including at least three from Hyderabad, are all set to announce major investments to set up new facilities in the United States during the 2026 SelectUSA Investment Summit here on Tuesday.
According to sources, 12 Indian companies are going to announce their investment plans in the United States during the Investment Summit. Of these, eight are from the top 15 pharma companies in India.
The United States is the biggest market for Indian generic drug products by sales. Lupin, Aurobindo Pharma, Sun Pharma, and Dr Reddy’s Laboratories are top players, with some deriving over 30 per cent of their revenue from the US. Hyderabad-based Divi’s Laboratories supplies active pharma ingredients to major American pharma companies.
Last week, Sun Pharmaceutical Industries Ltd had announced a $12-billion deal to acquire New Jersey-based Organon & Co.
In the last one year, Indian pharma companies such as Zydus Lifesciences, Syngene International, Thirumalai Chemicals, Stallion Lab have expanded their footprint in the US either through acquisition or by constructing new manufacturing facilities.
Several US governors, meanwhile, pitched their respective states for investment from Indian entrepreneurs during an India Reception hosted by the Confederation of Indian Industries at the SelectUSA Investment Summit.
While Delaware Governor Matt Meyer emphasised on business-friendly ecosystems in his state, Maryland Governor Aruna Miller focused on her state’s diversity, with a special reference to a large Indian diaspora.
According to Brandon Remington, US deputy undersecretary (policy and international trade administration) in the department of commerce, the total stock of foreign direct investment from India to the United States was approximately $16.4 billion, which supported about 70,800 jobs, $313 million in research and development spending and $1.5 billion worth of exports.
